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Umbilical cord blood transplantation (UCBT) is an important
alternative treatment modality for patients in need of an
allogeneic stem cell transplantation but lacking a matched-
sibling or unrelated stem cell donor.1 However, the availability
of a sufﬁciently sized cord blood unit may pose a problem for
adult patients.2 Double-UCBT (dUCBT) was developed in order
to increase cell dose and allow adult patients lacking a
sufﬁciently sized single cord blood unit (CBU) to proceed for
transplantation.3 Strikingly, it appeared that hematopoietic
recovery originated only from a single CBU in the majority of the
cases.3 Gutman et al showed that alloreactive interferon-g
secreting CD8+ T-cells were present early after dUCBT.4
Subsequently, we showed that CD4+ T-cells expand early after
transplantation and CD4+ T-cell chimerism predicts for graft
predominance.5,6 Given these observations we hypothesized that
HLA-class II speciﬁc CD4+ T-cells from the ‘winner’ cordmay be
responsible for rejection of the ‘loser’ cord. That hypothesis was
retrospectively supported by demonstrating the presence of
alloreactive, HLA-class II speciﬁc effector CD4+ T-cells in a
limited number of patients.7 In addition, alloreactivity was
also detected towards primary leukemic cells when the HLA-
class II allele mismatches were shared with de NE-CBU. In the
present study, we set out to prospectively test this hypothesis in a
phase II study.7
A total of 70 patients aged 18 to 70 years, with high-risk
hematological disease, eligible for a UCBT were included in the
HOVON 115 study, a prospective, multicenter phase II trial
(EudraCT 2012-001188-55). The primary endpoint was the
proportion of evaluable patients with activated class-II speciﬁc T-
cells. Patients received reduced intensity conditioning consisting
of cyclophosphamide 60mg/kg; ﬂudarabine 4  40mg/m2;
TBI 2  2 Gy. Peripheral blood (PB) from patients were collected
at 1 to 3 months after dUCBT for chimerism analysis and
isolating PB-mononuclear cells (PBMCs). HLA-class II negative
HeLa cells were retrovirally transduced with single HLA-DRA1/
B1, HLA-DQA1/B1 or HLA-DPA1/B1 molecules, based on the
mismatched allele from the NE-CBU. Post-dUCBT PBMCs were
cocultured with irradiated single HLA-class II molecule trans-
duced HeLa cells and with addition of a cytokine mixture to
propagate T-cells.7 Subsequently CD4+ T-cell activation was
assessed by ﬂow cytometry using antigens and effector markers,
as described.7 Alloreactivity was measured as ‘fold increase (FI)
[%CD137+/CD4+]’ of reactivity toward HeLa cells transduced
with mismatched HLA-class II alleles relative to reactivity
towards the not-transduced ‘empty’ HeLa cell.
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Two patients were not transplanted because of withdrawal of
consent and rapid progression of the underlying disease, andwere
therefore excluded from all analyses. Patients’ characteristics of
the remaining 68 patients are described in Table 1. The majority
of the patients were diagnosed with acute myeloid leukemia or
myelodysplastic syndrome with a low WHO performance- and
HCT-CI score. There were no signiﬁcant differences in the
number of infused nucleated-, viable CD34+ and CD3+ cells
between winner- and loser-CBU (Table 2; P0.81, P0.19 and
P0.27, respectively; Mann-Whitney test). One-year overall
survival (OS) and progression free survival (PFS) from 1st UCBT
were 61% (95% conﬁdence interval (CI) 49–72%) and 60%
(95% CI 47–70%) respectively (Supplementary Fig. 1, Supple-
mental Digital Content, http://links.lww.com/HS/A42), with
median follow-up of 48.2 months (range, 3.2–65.7 months)
among the 36 patients still alive. Non-relapse mortality at 12
months was 28% (standard error (SE), 5%) and the cumulative
incidence of relapse (or progression) at 12 months was 12% (SE,
4%). Engraftment was observed in 62 out of 68 (91%) patients
with a median time to neutrophil recovery >0.5109/L of 31
days. Primary graft failure occurred in 3 patients. Complete single
donor chimerism was established in 62 out of 68 (91%) patients.
HLA-class II mismatches between the 2 transplanted cords were
present in 42 out of these patients. In vitro tests could be
performed for 20 of the 42 patients for which an HLA-class II–
transduced HeLa cell was available. T-cell numbers increased
6.7-fold (median; range, 0.2–192.4) after the HLA-class II allele-
speciﬁc propagation of the post-dUCBT PBMC samples. In 18
out of the 20 (90%) patients tested, alloreactive CD4+ T-cells
toward 1 or more HLA-class II mismatched alleles of the NE-
CBUwere detected, which is much higher than the 50%whichwe
used for the sample size calculation. Of note, our in-vitro
expansion protocols may have favored CD4+ T-cells over CD8+
T-cells as a result of the use of HLA-class II antigens for
expansion. In total, CD4+ T-cell alloreactivity toward 24 of 26
(92%) mismatched alleles was detected, including 9 out of 9
(100%) for DR, 10 out of 12 (83%) for DQ and 5 out of 5
(100%) for DP alleles early (median: 1 month; range: 1–3
months) after double cord blood transplantation (Fig. 1). CD4+
T-cell alloreactivity towards DR,DQ andDP alleles were 9.3-fold
(range, 3.4–44.0), 8.9-fold (range, 1.7–37.8) and 7.3-fold (5.7–
31.4) increased as compared to reactivity towards the not
transduced ‘empty’ HeLa cell, respectively. A positive CD4+ T-
cell response towards ‘control’ matched alleles of the PD-CBU
were observed in 7 out of 26 (27%) tested alleles. The magnitude
of the CD4+ T-cell response was signiﬁcantly higher towards
mismatched alleles as compared to matched alleles, median FI 8.9
(range, 1.7–44) vs median FI 1.7 (range, 0.2–10.1; P< .01;
Mann–Whitney test), respectively.
Double UCBT was initially developed to allow transplantation
for adult patients lacking a sufﬁciently sized single CBU. It
resulted in less graft failure in comparison to single UCBT, but
with only 1 cord surviving in most cases.We recently reported the
presence of alloreactive HLA-class II speciﬁc CD4+ T-cells early
after transplantation.7 In the current study, we set out to
prospectively test the hypothesis whether alloreactive HLA-class
II speciﬁc CD4+ T-cells from the dominant UCB unit expand
early after and transplantation andmight be responsible for rapid
rejection of the "loser” unit. Here we show the presence of such
T-cells in 18 out of 20 patients and alloreactivity towards 24 of
26 tested alleles, further suggesting an important role for
alloreactive CD4+ T-cells from the ‘winner’ cord in rapid
rejection of the ‘loser’ cord. Rapid immunization of alloreactive
CD4+ T-cells by mismatched HLA-class II antigens might occur
by circulating class II expressing cells after infusion of both
UCB’s. Strong expression and/or a high number of class II + cells
might then evoke a rapid CD4+ T-cell response. This hypothesis
may, in part, be supported by ﬁndings by Purtill et al,8 who
showed that the NE-CBU total nucleated cell dose (as a surrogate
of a high number of class II expressing cells) was signiﬁcantly
associated with neutrophil engraftment. Type and number of
class II mismatches might also play a role. Avery et al9 showed
that a better HLA match between both units is associated with a
mixed unit chimerism, but it is unclear how class II mismatches
behave in that respect as compared to class I mismatches. Given
the relatively low number of patients in our previous7 and present
study, we could not clarify the relative value of class I vs class II
mismatched in this respect. However, given the matching criteria
Table 1
Patients Characteristics
Number of patients 68
Diagnosis, n (%)
Acute myeloid leukemia 34 50
Myelodysplastic syndrome 12 18
Acute lymphoblastic leukemia 4 6
Multiple myeloma 1 1
Chronic myeloid leukemia 1 1
Chronic lymphocytic leukemia 6 9
Non-hodgkin lymphoma 7 10
Myeloprolipherative disease 2 3
Severe aplastic anemia 1 1
Gender, n (%)
Male 35 51
Female 33 49
Age, years, median (range) 57 (20–69)
Weight, kg, median (range) 74 (41–108)
WHO performance status, n (%)
WHO 0 33 49
WHO 1 31 46
WHO 2 2 3
Unknown 2 3
HCT-CI Score, n (%)
0 42 62
1 19 28
2 3 4
3 3 4
4 1 1
CMV status patient, n (%)
negative 26 38
positive 42 62
CMV=cytomegalovirus, HCT-CI=hematopoietic cell transplant comorbidity index, WHO=World
Health organization.
Table 2
Graft Characteristics
Cord blood unit Winner Loser
Number of infused, median (range)
Nucelated cells (106/kg) 26.0 (0.3–62.4) 26.3 (0.2–73.7)
Viable CD34+ cells (103/kg) 34.9 (0.0–140) 40.5 (0.1–430.0)
Viable CD3+ cells (103/kg) 1340.0 (51.7–6955.0) 1339.7 (45.6–11070.0)
HLA-class II mismatch, median (range)
Recipient 2 (0–6) 1 (0–6)
Winner – 2 (0–5)
CMV=cytomegalovirus, HCT-CI=hematopoietic cell transplant comorbidity index, WHO=World
Health organization.
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for UCB-search, class II mismatches are more abundant than class
I mismatches.
The graft-vs-graft T-cell alloreactivity towards mismatched
precursor cells may result in unit predominance but also into
enhanced graft vs leukemia (GvL),10 especially if the alloreactive
CD4+ T-cell response is also directed towards a mismatched
allele present on recipient tissue and recipient leukemia cells.7
The relevance of HLA-class II was indirectly supported recently
by Christopher et al,11 who showed that loss of HLA-class II
expression is a mechanism by which relapsing tumors may
escape immune surveillance. Immunization of CD4+ T-cells
might occur by mismatched class II presenting leukemic cells
and antigen presenting cells (APCs) in tissues, in which these
cells are abundantly present accompanied by contributing
inﬂammatory signals. Such tissues may include the spleen, lung,
and intestine, in which large numbers of antigen presenting cells
are present. Thus, a CD4+ T-cell mediated graft-vs-graft
alloreactivity may involve and enhance GvL in the dUCBT
setting and thereby provide a possible explanation for the
relatively low relapse rate associated with dUCBT.10 Encourag-
ingly, the cumulative incidence of relapse in was only 12%
(SE, 4%) in our cohort of high risk patients. Of note, although
dUCBTmay be associated with a stronger GvL in comparison to
a single UCBT, dUCBT is often accompanied by a higher
Figure 1. Twenty-six PBMC samples obtained from 20 patients at 1 to 3 months after dUCBT were propagated towards mismatched HLA-class II
alleles of the non-engraftingCBU in a T cell-Hela cell coculture, using a panel of Hela cell line, each transducedwith a single HLA-class II allele. T cell
expansion of individual cultures at day 21 in presented as Fold increase cell number. Propagated T cells were subsequently tested for (allo)reactivity towards that
same mismatched, and matched HLA-class II alleles. The response was quantiﬁed by CD137 upregulation on CD4+ T-cells [%CD137+/CD4+] and presented for
the alloreactivity as ‘Fold increase (FI) [%CD137+/CD4+]’ of reactivity towards HeLa cells transduced with mismatched HLA-class II alleles relative to reactivity
towards the not-transduced ‘empty’ HeLa cell. The level of T cell expansion, Control reactivity (towards matched alleles) and alloreactivity response is presented in a
4-color-grading scales.
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incidence of acute and chronic GvHD with similar survival
outcome.12,13 However, patients with a high risk of relapse,
such as those with detectable minimal residual disease, might
beneﬁt from a dUCBT.14,15
In conclusion, this study prospectively showed a rapid and
strong alloreactive CD4+ T-cell response towards the majority of
class II mismatches present and available for analysis in 24 of 26
testes alleles. These observations might explain, at least in part,
the mechanism behind single unit dominance and the lower
incidence of relapse after dUCBT in comparison to single UCBT.
However, predicting graft predominance remains a challenge and
further research into that direction is needed. In addition, the
question to what extent such alloreactive T-cells are present after
haplo-identical alloHSCT is of importance. While class II
mismatches are abundantly present in haplo-identical alloHSCT,
the stronger immunosuppression, especially anti-thymocyte
globulin and/or cyclophosphamide, needed to prevent GvHD
might blunt the CD4+ T-cell response with possible loss of GvL
activity. Currently we are conducting a study evaluating the
presence of these classes II speciﬁc T-cells after haplo-id
alloHSCT.
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